13P First-line subcutaneous amivantamab plus lazertinib in EGFR-mutated advanced NSCLC: Updated results from the PALOMA-2 study
Conclusions:The HER3 ADC YL202/BNT326 shows encouraging efficacy with a manageable safety profile (low neutropenia and ILD rates) in 2L+ non-sq/squamous NSCLC pts without AGA and confirms activity in EGFR-mutated pts.Based on these results, YL202/BNT326 is being evaluated in combination with pumitamig (BNT327), an investigational anti-PD-L1xVEGF-A bispecific antibody, in NSCLC (NCT07111520).Clinical trial identification: NCT06107686.
Authors
- J.L. Tan
- Louise Medley (ORCID: https://orcid.org/0000-0003-0725-3812)
- S.C. Scott
- Kai Tang (ORCID: https://orcid.org/0000-0002-5369-9084)
- C.H. Andrade Teixeira
- Ali Alhadab
- E. Felip
- M. Wang
- M. Nagasaka
- S. Das
- J. Zhang
- P-J. Voon
- J. Dias
- J. Xie
- S. Shah
- A. Rittmeyer
- B. Massuti Sureda
- S.M. Lim
- N. Girard
Institutions
- Hebron University (PS)
- University Malaya Medical Centre (MY)
- Johnson & Johnson (United States) (US)
- Johns Hopkins University (US)
- Sun Yat-sen University (CN)
- Yonsei University (KR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Saclay (FR)
- Sarawak General Hospital (MY)
- University of Malaya (MY)
- Hospital de Câncer de Barretos (BR)
- University of California, Irvine Medical Center (US)
- Hospital Alemão Oswaldo Cruz (BR)
- Vall d'Hebron Hospital Universitari (ES)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- Institut du Thorax (FR)
- Torbay and South Devon NHS Foundation Trust (GB)
- Johnson & Johnson (India) (IN)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106320
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00